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cell populations without changes in cell division (as measured by
Ki67 expression) and recent thymic emigrants (as measured by T
cell receptor excision circles TREC) were observed with 4-week
courses of IGF-1 treatment. Signiﬁcantly, these changes were not
observed in similarly treated thymectomized mice, indicating that
effects of IGF-1 on peripheral T cell populations resulted primar-
ily from enhanced thymic output. IGF-1 administration also af-
fected thymic epithelial cell (TEC) turnover as measured by BrdU
incorporation, with observable shifts in TEC subpopulations in the
thymic cortex and medulla as enumerated by ﬂow cytometry.
Immunohistoﬂuorescence of extracellular matrix (ECM) in IGF-1
treated young, aged, and RAG KO mice were signiﬁcant for
changes in laminin distribution. Finally, mice lacking IGF-1 re-
ceptor (IGF-1R) signaling on T cells were generated through T
cell speciﬁc cre-mediated deletion of the IGF-1R high-afﬁnity
binding site (LCK-cre/loxIGF1R). Compared to wild-type litter-
mates, LCK-cre-loxIGF1R mice exhibited a decrease in the num-
ber of CD4 CD8 thymocytes, thymic TREC, splenic naive T
cell populations, and splenic TREC. These results demonstrate: (1)
IGF-1 enhances the recruitment of thymocyte precursors, expands
thymocyte subpopulations, and increases thymic output; (2) IGF-1
affects TEC turnover and ECM distribution, suggesting a mech-
anism by which IGF-1 inﬂuences thymocyte development; and (3)
IGF-1R signaling is required for the maintenance of normal thy-
mocyte and peripheral T cell populations. Together, the results
support the concept of the use of neuroendocrine growth factors
such as IGF-1 in preserving and/or enhancing recovery of thymic
function following HSCT.
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ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN SPECIFIC CD8 MEMORY
CELLS RESPOND DIFFERENTLY TO ANTIGEN AND ANTIGEN-INDEPEN-
DENT ACTIVATION IN THE SPLEEN AND MARROW COMPARTMENTS
FOLLOWING HCT
Shatry, A.1, Levy, R.B.1 University of Miami Miller School of Medicine,
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We are interested in studying how CD8 memory cells respond in
recipients following progenitor cell transplants. Antigen-speciﬁc
CD8 TM against the immunodominant H60 antigen in B6 mice
contribute to resistance against MHC-matched BALB.B marrow.
To examine CD8 TM responses to this antigen, B6 mice were
sensitized 2 with BALB.B antigen (B6BALB.B) and 1, 5, and 22
days later, H60-speciﬁc CD8 TM in the spleen and marrow were
analyzed for degranulation as assessed by CD107a expression. One
day following antigen administration, degranulation by CD8 TM
was equivalent (90%) in host spleen and marrow. Five days later,
degranulation of splenic H60 CD8 TM (60%) was 3 higher
(22%) versus cells in the marrow compartment. These levels de-
creased to 25% and 12%, respectively, in the spleen and marrow 3
weeks post antigen boost. These results indicated that CD8 TM
effector-like activity is induced asymmetrically in the 2 compart-
ments and this activity may be differentially regulated in these
locations. We then compared MiHA-speciﬁc CD8 TM in the
marrow and spleen after antigen-independent (lymphopenia) acti-
vation. Highly enriched (	95% pure) CFSE labeled or unlabeled
donor splenic CD8 T cells from B6BALB.B mice were adoptively
co-transplanted with syngeneic marrow to ablatively conditioned
(9.0 Gy) syngeneic hosts. Three days post-transfer, donor CD8
TM in recipient marrow and spleen were analyzed for CFSE
dilution and degranulation including H60 CD8 TM cells. Donor
H60 CD8 TM in the marrow underwent multiple cycles of
division in contrast to the spleen, indicating that the marrow
compartment provided superior support for this initial homeostatic
proliferation. Interestingly, 92% of donor H60 CD8 TM in
recipient spleens expressed CD 107a compared to 42% in the
marrow compartment. In total, these ﬁndings indicate that whereas
the marrow supported greater homeostatic proliferation of donor
CD8 TM versus the spleen, the latter compartment was the pre-
ferred site for effector-like activity induced by lymphopenic con-
ditions. These ﬁndings underscore the importance of hematopoi-
etic compartments in shaping the diversity and differentiation of
allospeciﬁc CD8 TM responses in the transplant setting.
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Background: CMV infection is an important cause of morbidity
and mortality in SCT recipients despite the introduction of routine
post-transplant virologic monitoring and the use of potent antiviral
agents. This prospective multicenter study evaluated the use of
tetramers in monitoring CMV-speciﬁc T cell recovery following
allogeneic SCT to predict patients at risk for CMV-related com-
plications. Methods: Patients were tested every 2 weeks and mon-
itored for up to 1 year post-transplant. iTAg™ MHC Tetramers
(Beckman Coulter, San Diego) were used to enumerate CMV-
speciﬁc CD8 T cells by ﬂow cytometry using a single-platform
absolute counting method. The following tetramers were included:
pp50: A0101 VTEHDTLLY; pp65: A0201 NLVPMVATV,
B0702 TPRVTGGGAM, B3501 IPSINVHHY; IE-1: B0801
ELRRKMMYM. All patients underwent weekly surveillance by
pp65 antigenemia or DNAemia with preemptive antiviral therapy.
Results: Data were analyzed for 83 CMV-seropositive recipients
with 3 or more tetramer values. Median follow-up was 9 months
(range 2–12). Delayed recovery of CMV-speciﬁc CD8 T cells
(7 cells/mL in all blood samples during the ﬁrst 65 days post-
transplant) predisposes patients to CMV-related complications
(Table 1). These patients are 2.6 times more likely to develop
recurrent or persistent CMV infection, 4.8 times more likely to
develop CMV disease, 2.4 times more likely to develop fatal com-
plications, and 2.2 times more likely to develop one of more of
these outcomes than patients showing rapid recovery. Rapid re-
covery (7 cells/mL in any blood sample during the ﬁrst 65 days
post-transplant) was associated with protection from CMV-related
complications. Inter- and intraassay variability of the assay was
8% and 8%, and results were available in 3 hours. Conclu-
sions: CMV tetramer-based immune monitoring, in conjunction
with virologic monitoring, can be an important new tool that
permits clinicians to assess the period of risk of CMV-related
complications and to make appropriate preemptive therapeutic
choices in managing allogeneic SCT patients. For high-risk pa-
tients with delayed immunologic recovery, virologic monitoring,
CMV tetramer monitoring, and other preemptive strategies should
be continued beyond 100 days post-transplant. For low-risk pa-
tients (7 tetramer-positive cells/mL), studies are needed to de-
termine how long virologic monitoring should be continued or if
preemptive therapy may be modiﬁed or instituted at higher viral
load levels (Table 1).
Table 1. Relative Risk
Recurrent or
Persistent
CMV Infection
CMV
Disease
Transplant-
Related
Mortality
Composite
(one or More
of These
Outcomes)
Delayed recovery
of CMV-specific
CD8 cells
(< 7 cells/uL)
2.6 4.8 2.4 2.2
P  .02 P  .09 P  .12 P  .01
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EFFECTS OF THYMOGLOBULIN ON LYMPHOCYTE L-SELECTIN-MEDI-
ATED ADHESIVE INTERACTIONS
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